Haleon (HLN) FCF Payout Ratio (2021 - 2023)

Haleon (HLN) posted FCF Payout Ratio of 1.82 for Q4 2023, down 2003.67% on a QoQ basis from 0.1 in Q4 2022, and down 2003.67% year-over-year from 0.1 in Q4 2022.

Haleon (HLN) FCF Payout Ratio (2021 - 2023) Analysis & Trends

Haleon's FCF Payout Ratio history runs 3 years deep, the most recent figure standing at 1.82 for Q4 2023.

  • Quarterly FCF Payout Ratio fell 2003.67% year-over-year to 1.82 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 0.3 (changed N/A YoY) and the FY2025 annual result came in at 0.26, down 4.75% from the prior year.
  • FCF Payout Ratio was 1.82 for Q4 2023 at Haleon, down from 0.1 in the prior quarter.
  • Across five years, FCF Payout Ratio topped out at 0.1 in Q3 2022 and bottomed at 6.98 in Q4 2021.
  • A 3-year average of 2.15 and a median of 0.86 in 2022 frame the typical range for FCF Payout Ratio.
  • Annual changes were most pronounced in 2022 — FCF Payout Ratio jumped 101.37% — and 2023, when it slumped 2003.67%.
  • Haleon's FCF Payout Ratio stood at 6.98 in 2021, then soared by 101.37% to 0.1 in 2022, then slumped by 2003.67% to 1.82 in 2023.
  • Business Quant data shows HLN's FCF Payout Ratio at 1.82 in Q4 2023, 0.1 in Q4 2022, and 0.1 in Q3 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Cover (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn -
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 0.77
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -10.50
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 0.40
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn -
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -
10 Vireo Growth 10.57 Bn 10.41 Bn 59.30 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2023 -1.82
Dec 31, 2022 0.10
Sep 20, 2022 0.10
Dec 31, 2021 -6.98